Value of programmed cell death ligand 1 and soluble programmed cell death ligand 1 in predicting the prognosis of hepatocellular carcinoma and related controversies / 临床肝胆病杂志

ABSTRACT

At present, there are various treatment methods for hepatocellular carcinoma (HCC), including surgical treatment, interventional treatment, and immunotherapy, and even so, the five-year survival rate of HCC patients is only 12.5%. Influencing factors for the prognosis of HCC have always been the focus of research. With the in-depth research on programmed cell death protein 1 (PD-1) inhibitors in the treatment of HCC in recent years, the role of programmed cell death ligand 1 (PD-L1) and soluble programmed cell death ligand 1 (sPD-L1), as the ligands of PD-1, in immune escape and their value in predicting prognosis have attracted more and more attention. This article elaborates on the current controversies, consensus, and advances in PD-L1 and sPD-L1 as immune markers in evaluating the prognosis of HCC.